leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics expedites development of 5-minute coronavirus saliva test in Germany

Xphyto and its partner 3a-Diagnostics are developing a point-of-care lateral flow test to detect viral RNA in patent saliva

Coronavirus graphic
3a’s enhanced RNA probe system has proven capable of detecting viral RNA in symptomatic, pre-symptomatic and asymptomatic patients alike

XPhyto Therapeutics Corp (CSE:XPHY) (OTCPINK:XPHYF) told investors Monday that development of its rapid saliva-based coronavirus (COVID-19) test is proceeding at an expedited basis at its diagnostic partner’s research lab in Germany. 

Xphyto and 3a Diagnostics GmbH are developing a point-of-care lateral flow test to detect viral RNA in patent saliva, as well as from nasal and throat swabs, in fewer than five minutes. 

3a’s enhanced RNA probe system has proven capable of detecting viral RNA in symptomatic, pre-symptomatic and asymptomatic patients alike, the company said.

READ: XPhyto Therapeutics says COVID-19 rapid screening test prototype achieves validation

The parties hope to win approval from European regulators in the first quarter of 2021, pending fast track certification from the German government, with commercial sales to follow soon after. 

In addition to COVID-19, the lateral flow is capable of detecting the broader family of coronaviruses. 

Prototype testing has confirmed successful activation of both the “COVID-19 specific probes” and the “universal coronavirus probes at viral RNA levels,” XPhyto noted in a statement.

The Vancouver-based company also announced that it is presenting at today’s Wall Street Reporter Next Super Stock Live virtual event at 12:30 pm ET.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: XPhyto Therapeutics Corp.

Price: 2.35 CAD

CSE:XPHY
Market: CSE
Market Cap: $136.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics continues to move toward commercialization of their...

XPhyto Therapeutics (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on their plans to go to market in Europe with their testing program for the COVID-19 Rogers talks about where that program is AT and also about their drug delivery platform...

3 weeks, 6 days ago

2 min read